NCT02194595View on ClinicalTrials.gov

Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)

PHASE3CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2021

Study Completion Date

February 28, 2022

Conditions
Type 2 Diabetes
Interventions
DRUG

Basal insulin and exenatide

DRUG

Basal insulin only

DRUG

Basal insulin and bolus insulin

Trial Locations (1)

M5G1X5

Mount Sinai Hospital, Toronto

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

University of Toronto

OTHER

lead

Mount Sinai Hospital, Canada

OTHER

NCT02194595 - Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) | Biotech Hunter | Biotech Hunter